# Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

> **NCT01093794** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 28 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Co-administration of 50 mg sitagliptin and 500 mg metformin
- **DRUG:** sitagliptin/metformin 50 mg/500 mg tablet
- **DRUG:** Co-administration of 50 mg sitagliptin and 850 mg metformin
- **DRUG:** sitagliptin/metformin 50 mg/850 mg tablet

## Key facts

- **NCT ID:** NCT01093794
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093794, "Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01093794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*